K A Wafford
Overview
Explore the profile of K A Wafford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holton C, Hanley N, Shanks E, Oxley P, McCarthy A, Eastwood B, et al.
Alzheimers Res Ther
. 2020 Jul;
12(1):84.
PMID: 32669112
Background: Disturbed sleep is associated with cognitive decline in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). The progressive sequence of how neurodegeneration affects aspects of sleep...
2.
Witkin J, Mitchell S, Wafford K, Carter G, Gilmour G, Li J, et al.
J Pharmacol Exp Ther
. 2017 Feb;
361(1):68-86.
PMID: 28138040
The ability of the -methyl-d-aspartate receptor antagonist ketamine to alleviate symptoms in patients suffering from treatment-resistant depression (TRD) is well documented. In this paper, we directly compare in vivo biologic...
3.
Steinberg E, Wafford K, Brickley S, Franks N, Wisden W
Pflugers Arch
. 2014 Dec;
467(5):907-16.
PMID: 25482669
Tandem two-pore potassium channels (K2Ps) have widespread expression in the central nervous system and periphery where they contribute to background membrane conductance. Some general anaesthetics promote the opening of some...
4.
Wodarski R, Schuh-Hofer S, Yurek D, Wafford K, Gilmour G, Treede R, et al.
Eur J Pain
. 2014 Sep;
19(4):554-66.
PMID: 25195796
Background: Sleep disturbance is a commonly reported co-morbidity in chronic pain patients, and conversely, disruption of sleep can cause acute and long-lasting hypersensitivity to painful stimuli. The underlying mechanisms of...
5.
Jensen M, Wafford K, Brown A, Belelli D, Lambert J, Mirza N
Br J Pharmacol
. 2012 Oct;
168(5):1118-32.
PMID: 23061935
Background And Purpose: Most GABA(A) receptor subtypes comprise 2α, 2β and 1γ subunit, although for some isoforms, a δ replaces a γ-subunit. Extrasynaptic δ-GABA(A) receptors are important therapeutic targets, but...
6.
Phillips K, Cotel M, McCarthy A, Edgar D, Tricklebank M, ONeill M, et al.
Neuropharmacology
. 2011 Apr;
62(3):1359-70.
PMID: 21521646
Neuroanatomical, electrophysiological and behavioural abnormalities following timed prenatal methylazoxymethanol acetate (MAM) treatment in rats model changes observed in schizophrenia. In particular, MAM treatment on gestational day 17 (E17) preferentially disrupts...
7.
Atack J, Hallett D, Tye S, Wafford K, Ryan C, Sanabria-Bohorquez S, et al.
J Psychopharmacol
. 2010 Feb;
25(3):329-44.
PMID: 20156926
In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABA(A) receptor occupancy (∼10%). Since it was not clear whether this sedation...
8.
Atack J, Wafford K, Street L, Dawson G, Tye S, Van Laere K, et al.
J Psychopharmacol
. 2010 Feb;
25(3):314-28.
PMID: 20147571
MRK-409 binds to α1-, α2-, α3- and α5-containing human recombinant GABA(A) receptors with comparable high affinity (0.21-0.40 nM). However, MRK-409 has greater agonist efficacy at the α3 compared with α1...
9.
Wafford K, van Niel M, Ma Q, Horridge E, Herd M, Peden D, et al.
Neuropharmacology
. 2008 Sep;
56(1):182-9.
PMID: 18762200
Inhibition in the brain is dominated by the neurotransmitter gamma-aminobutyric acid (GABA); operating through GABA(A) receptors. This form of neural inhibition was presumed to be mediated by synaptic receptors, however...
10.
Dawson G, Maubach K, Collinson N, Cobain M, Everitt B, MacLeod A, et al.
J Pharmacol Exp Ther
. 2005 Dec;
316(3):1335-45.
PMID: 16326923
Alpha5IA is a compound that binds with equivalent subnanomolar affinity to the benzodiazepine (BZ) site of GABA(A) receptors containing an alpha1, alpha2, alpha3, or alpha5 subunit but has inverse agonist...